FDAnews
www.fdanews.com/articles/149207-fed-circ-revives-santarus-rsquo-suit-over-par-rsquo-s-generic-zegerid

Fed. Circ. Revives Santarus’ Suit Over Par’s Generic Zegerid

September 5, 2012
The Federal Circuit partially revived Santarus’ bid to block Par Pharmaceutical’s generic version of the heartburn drug Zegerid (omeprazole/sodium bicarbonate), reversing a lower court’s ruling that claims of two patents governing the drugs’ absorption were invalidated by obviousness.
Law360